Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma [Yahoo! Finance]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Yahoo! Finance
therapy, is pleased to announce that its collaboration partner ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program. As part of the research collaboration agreement entered into between Aarvik and ArriVent on December 21, 2021, Aarvik has been responsible for discovery and preclinical development of a novel ADC molecule that relies on the unique modular platform developed by Aarvik. ArriVent will be responsible for clinical development and commercialization. Aarvik has received an upfront payment, research funding and an opt-in payment, and is eligible to receive contingent development and commercial milestones, plus royalties. "Aarvik has shown that it can combine the most advanced protein engineering technologies with deep ADC drug development expertise to enable next-generation, best-in-class oncology therapies," said Jagath Reddy Junutula , PhD, Co-founder, President and CEO of Aarvik Therapeutics. "Aarvik will continue to pursue p
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]Seeking Alpha
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $39.00 price target on the stock, up previously from $35.00.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
AVBP
Earnings
- 8/14/24 - In-Line
AVBP
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- AVBP's page on the SEC website